FeesSafety
Pluang+

Pyth Network expands market data with 24/7 U.S. equities, ETFs, indices, plus new agricultural and cotton futures data.

Protocol Fundamentals
08 Nov 2026, 18:40 WIB
Tokenpost
View Source
Bullish
Pyth Network expands market data with 24/7 U.S. equities, ETFs, indices, plus new agricultural and cotton futures data.

Pyth Network has broadened its market-data offerings to include U.S. equities, exchange-traded funds (ETFs), and indices accessible around the clock across global markets. The expansion also adds new agricultural indices and cotton futures to its data lineup. Pyth provides crucial price data to decentralized applications and perpetual futures markets, supporting significant trading activity. In Q3, markets using Pyth data accounted for $2.04 trillion in real-world-asset perpetual volume, representing 94.4% of the $2.16 trillion total tracked, highlighting Pyth's dominant role in these markets.

Pyth Network's expansion into U.S. equities, ETFs, and global indices offers new market data options. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Nov 08, 2026 23:21 WIB: out of 50 major cryptocurrencies priced, 13 rose and 36 fell today. Notable movers include SXP (Solar) down 46.27% at Rp37, BAL (Balancer) up 11.14% at Rp16.297, and EOS (EOS.IO) up 8.13% at Rp12.649, with typical hold times ranging from 85 to 94 days on Pluang.

More News

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...

Market News
Bullish
2 hours ago
CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...

Market News
Bullish
2 hours ago
Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...

Others
Neutral
2 hours ago
New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...

Market News
Bullish
2 hours ago
Binance to close accounts in France, Spain, Italy, Poland by Dec 31, 2026, charging monthly fees from Nov 29.

Binance to close accounts in France, Spain, Italy, Poland by Dec 31, 2026, charging monthly fees from Nov 29.

Binance is closing customer accounts in France, Spain, Italy, and Poland by December 31, 2026, following the end of its EU licenses under MiCA regulations. From November 29, a monthly administrative fee of 0.025% of holdings or a minimum of 10 USDC w...

Market News
Bearish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App